ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
Northern TK Venture Pte Ltd, Fortis Healthcare's promoter, has appealed a Tokyo District Court judgment to the Tokyo High Court. The litigation concerns losses related to delayed tender offer approvals.
Fortis Hospotel signed definitive agreements with SLJ Society to provide healthcare services at their 400+ bed hospital. Fortis will provide a ₹567 Crore loan.
Tokyo District Court dismissed all NTK claims against Daiichi Sankyo; NTK must bear litigation costs. NTK is reviewing the judgment and evaluating appeal options.
Management conference call discussing a Delhi High Court order regarding a forensic audit. Operating plans, including capex, bed expansion, and M&A, remain unaffected and fully funded by internal accruals.
The Delhi High Court has ordered a forensic audit concerning shareholding changes and control of Fortis Healthcare's erstwhile promoters. The company faces no liability or penalty.
Fortis Healthcare Limited received a voluntary ESG rating for FY 2025-26 from Crisil ESG Ratings & Analytics Ltd, with a rating category of 'Strong'.
Fortis Healthcare held its 30th Annual General Meeting on August 11, 2026. Shareholders considered resolutions for financial statement adoption, a Rs. 1 per share dividend, and director re-appointments.
Fortis Q1FY27 consolidated revenue grew 17.5% YoY to INR 2,545 Cr. Consolidated Operating EBITDA rose 15.8% to INR 568 Cr with a 22.3% margin.
Fortis Healthcare reported consolidated revenues of INR 2,545 Crore for Q1 FY27. The company's press release highlights operational performance across its hospital and diagnostics business segments.
Fortis Healthcare Ltd reported revenue from operations of ₹2,545 Cr (+17.5% YoY) and net profit of ₹272.8 Cr (+2.2% YoY) for Q1 FY27.
Fortis Healthcare's board approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, and appointed new tax auditors.
Fortis Healthcare Limited announced an intra-group merger involving its material subsidiary, Agilus Diagnostics Limited, and two of its wholly-owned subsidiaries.
Fortis Healthcare Limited announced a board meeting on August 06, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Fortis Healthcare Ltd filed its quarterly shareholding pattern as of June 30, 2026. The report details holdings across promoter, institutional, and public categories.
Fortis Healthcare announced the appointment of Mr. Vijender Singh as MD and CEO of its subsidiary, Agilus Diagnostics, effective July 20, 2026.
Fortis Healthcare fixed July 24, 2026, as the record date for a ₹1 per share final dividend. Payment is subject to shareholder approval at the upcoming AGM.
Fortis Healthcare convened its 30th AGM for August 11, 2026. Key agendas include dividend declaration and re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director.
Fortis Healthcare re‑appoints Dr. Ashutosh Raghuvanshi as CEO effective 19‑Mar‑2027 for a 24‑month term. The change was approved in the board meeting on 8‑Jul‑2026.
Fortis Healthcare's Board re‑appointed Dr. Ashutosh Raghuvanshi as Managing Director and CEO for two years from 19 Mar 2027. The decision was disclosed on 8 July 2026.
Fortis Healthcare expands into Odisha via an O&M deal for a 300-bed hospital in Cuttack. This asset-light model marks its first major presence in the state.
Fortis Healthcare filed its Annual Secretarial Compliance Report for FY 2025-26. The company reported high compliance, with one minor administrative penalty of ₹35,400 paid.
Fortis reported strong FY26 performance with 17.3% revenue growth and 31.5% PAT growth. Strategy focuses on brownfield expansion and diagnostic margin improvement.
Fortis Healthcare recommended a final dividend of 0.1 per equity share for FY 2025-26. The record date and general meeting details will be announced later.
Fortis Healthcare Limited appointed M/s. Jitender, Navneet & Co. as Cost Auditors for a 12-month tenure. The experienced firm's appointment ensures statutory costing compliance.
Fortis Healthcare reported consolidated revenue of ₹9,128 Crore for FY26, marking a 17.3% growth. The board recommended a dividend of ₹1 per share for shareholders.
Fortis Healthcare Ltd reported revenue from operations of ₹2,365 Cr (+17.8% YoY) and net profit of ₹271.2 Cr (+44.3% YoY) for Q4 FY26.
Fortis Healthcare approved FY26 financial results and recommended a ₹1 per share final dividend. The dividend involves a ₹7.55 Crore cash outflow, reflecting stable shareholder returns.
Fortis Healthcare provided an update on litigation filed by its promoter, Northern TK Venture, against Daiichi Sankyo in Japan. The Tokyo District Court has concluded proceedings, with a judgment scheduled for September 10, 2026. This follow-up stems from an April 28, 2026, announcement by IHH Healthcare Berhad regarding the same matter.
Fortis Healthcare Limited approved the grant of 1,32,05,200 stock options to eligible employees under its ESOP 2026 scheme. The options have an exercise price of INR 923.10 each. This move aims to align employee interests with long-term shareholder value and talent retention.
Fortis Healthcare Limited submitted its annual centralized database disclosure for Non-Convertible Debentures (NCDs) for FY 2025-26. The filing details three NCD series totaling ₹1,550 Crore, including listing information, credit rating upgrades to CRISIL AA+, and confirmation of timely annual interest payments made on December 22, 2025.